Balashova T S, Golega E N, Rud'ko I A, Balabolkin M I, Kubatiev A A
Probl Endokrinol (Mosk). 1994 May-Jun;40(3):12-5.
The aim of our research was elucidation of a relationship between red cell membrane lipid peroxidation (LPO) and antioxidant defense enzymes, on the one hand, and the age, disease duration, and presence of vascular complications in patients with type I diabetes mellitus, on the other. The possibility of correcting red cell peroxide status with human insulin preparations was investigated. Red cell membrane LPO was found increased more than twofold and antioxidant defense enzymes activities virtually unchanged vs. controls in 16 patients with diabetes aged 20 to 43. These characteristics of red cell peroxidation status do not depend on patients' age, disease standing, or presence of vascular complications. A twelve-week therapy with biosynthetic insulin resulted in complete normalization of LPO processes in patients with angiopathies aged under 35 and with disease standing of less than 10 years. In diabetics with angiopathies aged over 35 and disease standing of more than 10 years red cell MDA level reduced under the effect of therapy with human insulin preparations but was still increased vs. that in healthy donors by 1.5 times. Red cell GP and SOD activities reduced in the course of insulin therapy in all the examined groups of diabetics. Catalase activity increased by approximately 50% in patients with angiopathies, those aged over 35, and a disease standing of more than 10 years under the effect of insulin. In the rest groups of patients catalase activity did not differ from its initial level. Our results permit us recommending besides human insulin preparations antioxidant therapy for patients with vascular complications, those aged over 35, and a disease standing of more than 10 years.
我们研究的目的,一方面是阐明红细胞膜脂质过氧化(LPO)与抗氧化防御酶之间的关系,另一方面是阐明其与Ⅰ型糖尿病患者的年龄、病程以及血管并发症之间的关系。我们研究了用人胰岛素制剂纠正红细胞过氧化物状态的可能性。结果发现,16名年龄在20至43岁之间的糖尿病患者,其红细胞膜LPO比对照组增加了两倍多,而抗氧化防御酶的活性基本未变。红细胞过氧化状态的这些特征并不取决于患者的年龄、病程或血管并发症的存在情况。对35岁以下、病程小于10年且患有血管病变的患者进行为期12周的生物合成胰岛素治疗,可使LPO过程完全恢复正常。对于年龄超过35岁、病程超过10年且患有血管病变的糖尿病患者,人胰岛素制剂治疗可使红细胞丙二醛(MDA)水平降低,但仍比健康供体高1.5倍。在所有接受检查的糖尿病患者组中,胰岛素治疗过程中红细胞谷胱甘肽过氧化物酶(GP)和超氧化物歧化酶(SOD)的活性均降低。在胰岛素作用下,年龄超过35岁、病程超过10年且患有血管病变的患者,过氧化氢酶活性增加了约50%。在其余患者组中,过氧化氢酶活性与初始水平无差异。我们的研究结果使我们建议,除了人胰岛素制剂外,对于患有血管并发症、年龄超过35岁且病程超过10年的患者,还应进行抗氧化治疗。